Protagen at the Biotechnica 2010
UNIarray® serves as a unique technology platform to develop and validate novel, serum based molecular diagnostics and can be further applied in the development of biomarkers for therapy monitoring and companion diagnostics.
In-house research at Protagen is currently focused on the validation of proprietary biomarker panels for the diagnosis of Prostate Cancer and Multiple Sclerosis. Additional R&D activities are concentrating on Breast, Ovarian and Pancreas Cancer, as well as Morbus Parkinson, Rheumatoid Arthritis and Systemic Lupus Erythematodes.
Dr. Schulz-Knappe, CSO at Protagen AG will be presenting an update on the Prostate Cancer validation study at the Molecular Diagnostics Europe Conference (MDxEU), which will be co-hosted parallel to the Biotechnica meeting (5.10.2010 at 11.45 am. For further information please refer to http://www.moleculardiagnosticseu.com/...).
In addition, Dr. Angelika Lüking, Head of Research and Development at Protagen AG will be presenting an update on the Multiple Sclerosis program at the BMBF project forum (5.10. 2010 at 11.30 am, BMBF Forum).
You are cordially invited to meet us at the Biotechnica Partnering event or you can visit us at the BioNRW booth (Hall 9, E 16).
Über Protagen AG
Protagen AG (www.protagen.de) is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.